AstraZeneca To Partner With Quell In Buzzing Treg Field
Company Joins Peers In Investing In Regulatory T Cells
Executive Summary
AstraZeneca has paid $85m upfront to develop Tregs against two autoimmune conditions, type 1 diabetes and inflammatory bowel disease